| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sowmya K Surya, Ariel L Barka. GH receptor antagonist: mechanism of action and clinical utility. Reviews in endocrine & metabolic disorders. vol 6. issue 1. 2005-07-08. PMID:15711909. |
this review focuses on the development of gh receptor antagonist as a novel agent for treatment of acromegaly, its mechanism of action and potential areas of use. |
2005-07-08 |
2023-08-12 |
Not clear |
| Susannah V Rowles, L Prieto, X Badia, Steven M Shalet, Susan M Webb, Peter J Traine. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. The Journal of clinical endocrinology and metabolism. vol 90. issue 6. 2005-07-05. PMID:15755865. |
we have performed a cross-sectional study of qol in 80 patients [43 male (mean age, 54.2 yr; range, 20-84); median gh, 0.93ng/ml (range, <0.3 to 23.7); igf-i, 333.1 ng/ml (range, 47.7-899)] with acromegaly. |
2005-07-05 |
2023-08-12 |
Not clear |
| Svetozar S Damjanovic, Aleksandar N Neskovic, Milan S Petakov, Vera Popovic, Djuro Macut, Pavle Vukojevic, Miloje M Joksimovi. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure? Clinical endocrinology. vol 62. issue 4. 2005-07-05. PMID:15807870. |
correction of gh and igf-i levels are associated with improvements in insulin secretion, cardiac performance and body composition in patients with acromegaly, but whether these parallel post-treatment levels of gh-igf-i axis activity is undefined. |
2005-07-05 |
2023-08-12 |
Not clear |
| Jens O L Jørgensen, Morten Krag, Niels Jessen, Helene Nørrelund, Esben T Vestergaard, Niels Møller, Jens S Christianse. Growth hormone and glucose homeostasis. Hormone research. vol 62 Suppl 3. 2005-06-29. PMID:15539799. |
patients with active acromegaly are insulin-resistant and glucose-intolerant, whereas children with growth hormone (gh) deficiency (ghd) are insulin-sensitive and may develop fasting hypoglycaemia. |
2005-06-29 |
2023-08-12 |
Not clear |
| Ana Pokrajac-Simeunovic, Peter J Traine. Pitfalls in the diagnosis of acromegaly. Hormone research. vol 62 Suppl 3. 2005-06-29. PMID:15539804. |
a review of published experience suggests that the combination of a gh nadir during an oral glucose tolerance test of <0.25 microg/l plus a normal age-related insulin growth factor-i level makes the diagnosis of acromegaly extremely unlikely. |
2005-06-29 |
2023-08-12 |
Not clear |
| Ian M Holdawa. Treatment of acromegaly. Hormone research. vol 62 Suppl 3. 2005-06-29. PMID:15539805. |
mortality is increased in individuals with acromegaly unless serum growth hormone (gh) levels are below 2 microg/l and serum insulin-like growth factor (igf)-i levels are normal following treatment. |
2005-06-29 |
2023-08-12 |
Not clear |
| Ozay Tiryakioğlu, Nurhan U Caneroğlu, Erkan Yilmaz, Nurperi Gazioğlu, Pinar Kadioğlu, Ozer Açbay, Sadi Gündoğd. Familial acromegaly: a familial report and review of the literature. Endocrine research. vol 30. issue 2. 2005-06-28. PMID:15473133. |
a 31-year-old woman (subject a) and her 34-year-old sister (subject b) with elevated basal rolactin (prl) levels, elevated growth hormone (gh) levels during the oral glucose tolerance test (ogtt) and a pituitary adenoma in computed tomography (ct) and magnetic resonance imaging (mri) were diagnosed as acromegaly. |
2005-06-28 |
2023-08-12 |
human |
| Ozay Tiryakioğlu, Nurhan U Caneroğlu, Erkan Yilmaz, Nurperi Gazioğlu, Pinar Kadioğlu, Ozer Açbay, Sadi Gündoğd. Familial acromegaly: a familial report and review of the literature. Endocrine research. vol 30. issue 2. 2005-06-28. PMID:15473133. |
11 years later her 24-year-old son (subject c) also presented with typical signs of acromegaly, elevated basal prl level and elevated gh levels during ogtt. |
2005-06-28 |
2023-08-12 |
human |
| M L Isidro, P Iglesias Díaz, X Matías-Guiu, F Cordid. Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma. Journal of endocrinological investigation. vol 28. issue 2. 2005-06-20. PMID:15887863. |
in more than 95% of cases acromegaly is due to gh hypersecretion by a pituitary adenoma. |
2005-06-20 |
2023-08-12 |
Not clear |
| Michael O Thorne. Acromegaly and serum insulin-like growth factor I. Hormone research. vol 62 Suppl 1. 2005-06-17. PMID:15761230. |
measurements of both igf-i and gh are cornerstones of biochemical diagnosis and follow-up of acromegaly, although in patients treated with pegvisomant, igf-i levels should be followed rather than gh levels. |
2005-06-17 |
2023-08-12 |
Not clear |
| Angela N Paisley, Peter J Traine. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly. Hormone research. vol 62 Suppl 1. 2005-06-17. PMID:15761238. |
improvements in the quality of, and access to, igf-i assays has encouraged monitoring of acromegaly with igf-i, although circulating growth hormone (gh) and igf-i values provide different information, so ideally both should be monitored. |
2005-06-17 |
2023-08-12 |
Not clear |
| D Abraham, W T Couldwel. Bilateral testicular enlargement and seminoma in a patient with acromegaly. British journal of neurosurgery. vol 18. issue 6. 2005-06-13. PMID:15799199. |
we describe a patient with endogenous gh excess caused by a pituitary tumour, resulting in acromegaly. |
2005-06-13 |
2023-08-12 |
Not clear |
| D Abraham, W T Couldwel. Bilateral testicular enlargement and seminoma in a patient with acromegaly. British journal of neurosurgery. vol 18. issue 6. 2005-06-13. PMID:15799199. |
after resection of the pituitary tumour, gh levels fell below 0.5 ng/ml, with acromegaly resolution. |
2005-06-13 |
2023-08-12 |
Not clear |
| Jardena J Puder, Sujatha Nilavar, Kalmon D Post, Pamela U Fred. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 4. 2005-05-31. PMID:15634715. |
newly diagnosed and postoperative patients with acromegaly underwent assessment of fasting igf-i and fasting and postoral glucose tolerance test gh and insulin levels and completed a numeric signs and symptoms questionnaire. |
2005-05-31 |
2023-08-12 |
Not clear |
| Jardena J Puder, Sujatha Nilavar, Kalmon D Post, Pamela U Fred. Relationship between disease-related morbidity and biochemical markers of activity in patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 90. issue 4. 2005-05-31. PMID:15634715. |
our data indicate that overall and specifically in the presence of discordant serum igf-i and nadir gh levels, igf-i was more predictive than gh levels of insulin sensitivity and clinical symptom score in patients with acromegaly. |
2005-05-31 |
2023-08-12 |
Not clear |
| Alla A Sakharova, Eleni V Dimaraki, William F Chandler, Ariel L Barka. Clinically silent somatotropinomas may be biochemically active. The Journal of clinical endocrinology and metabolism. vol 90. issue 4. 2005-05-31. PMID:15671111. |
the diagnosis of acromegaly is suspected based on the typical clinical presentation and is subsequently confirmed biochemically by elevated gh and igf-i concentrations. |
2005-05-31 |
2023-08-12 |
Not clear |
| Dinesh Selvarajah, Jonathan Webster, Richard Ross, John Newell-Pric. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European journal of endocrinology. vol 152. issue 4. 2005-05-19. PMID:15817912. |
the excess mortality and morbidity associated with acromegaly are secondary to prolonged elevation of gh and igf-i. |
2005-05-19 |
2023-08-12 |
human |
| Dinesh Selvarajah, Jonathan Webster, Richard Ross, John Newell-Pric. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. European journal of endocrinology. vol 152. issue 4. 2005-05-19. PMID:15817912. |
dopamine agonists (das), a cheap alternative to sas, allow control of gh and igf-i in less than 20% of patients with acromegaly. |
2005-05-19 |
2023-08-12 |
human |
| Jens O L Jørgensen, Helene Nørrelund, Flavia Conceicao, Niels Møller, Jens S Christianse. Somatropin and glucose homeostasis: considerations for patient management. Treatments in endocrinology. vol 1. issue 4. 2005-04-26. PMID:15799216. |
accordingly, active acromegaly is characterized by insulin resistance at the hepatic and muscular level, whereas children with growth hormone (gh) deficiency are insulin hypersensitive and prone to developing fasting hypoglycemia. |
2005-04-26 |
2023-08-12 |
Not clear |
| Thor Uelan. GH/IGF-I and bone resorption in vivo and in vitro. European journal of endocrinology. vol 152. issue 3. 2005-04-19. PMID:15757846. |
in vivo studies in normal subjects, postmenopausal women and patients with excess or diminished gh production (acromegaly and ghd) indicate that both gh and igf-i activate osteoclasts, but that gh has a more pronounced effect, independently of igf-i. |
2005-04-19 |
2023-08-12 |
human |